THX Pharma
ALTHX.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$44.39M
Close$
$-0.16
105.2% downside
Current Fair Value
105.2% downsideOvervalued by 105.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $44.39 Million |
|---|---|
| Enterprise Value | $60.56 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.22 |
| Beta | 1.51 |
| Outstanding Shares | 14,506,672 |
Return
| Return on Equity | -190.55% |
|---|---|
| Return on Assets | -17.83% |
| Return on Invested Capital | -243.46% |
Valuation & Multiples
| P/E Ratio | -31.73 |
|---|---|
| PEG | 35.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14.8 |
| Enterprise Value to EBIT | -4.97 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 7.84 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About THX Pharma
12 employees
CEO: Mathieu Charvériat Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical...